Abstract:TNBC has the worst prognosis among all breast cancers, and survival in patients with recurrence is rarely beyond 12 months due to acquired resistance to chemotherapy, which is the standard of care for these patients. Our hypothesis is that Estrogen Receptor Beta 1 (ERB1) increases response to chemotherapy but is opposed by ERB4, which it preferentially dimerizes with. The role of ERB1 and ERB4 in influencing chemotherapy sensitivity has never been studied before. CAS9/CRSPR was used to truncate ERB1 Ligand Bin… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.